An autologous stem cell transplant is a procedure where your own blood-forming stem cells are collected, stored, and then returned to your body after you receive high-dose chemotherapy. The goal is to allow doctors to use aggressive cancer treatment that would otherwise permanently destroy your bone marrow, then rescue it with your own preserved stem cells. It’s the standard of care for eligible patients with multiple myeloma and certain lymphomas.
Why Your Own Cells Are Used
The word “autologous” simply means “from yourself.” Unlike a donor transplant, where someone else’s cells are used, this approach sidesteps the risk of your body rejecting foreign tissue. Your stem cells are collected before the intensive treatment begins, frozen, and given back to you afterward. Think of it as a biological insurance policy: doctors bank your healthy cells so they can hit the disease harder than would otherwise be safe.
These stem cells are hematopoietic, meaning they produce all the blood cells your body needs: red cells that carry oxygen, white cells that fight infection, and platelets that help with clotting. Once reinfused, they migrate back to your bone marrow and rebuild your entire blood system from scratch.
Conditions It Treats
Multiple myeloma is the most common reason for an autologous transplant. For younger patients with adequate organ function, it remains the standard first-line approach and has been for decades. Certain types of non-Hodgkin lymphoma and Hodgkin lymphoma are also treated this way, particularly when the disease has relapsed or hasn’t responded fully to initial chemotherapy.
Beyond cancer, the procedure is increasingly used for severe autoimmune diseases. The rationale is different: rather than rescuing the marrow after aggressive chemo, the goal is to wipe out a malfunctioning immune system entirely and let it regrow from stem cells into one that no longer attacks the body’s own tissues. This “immune reset” can establish a completely new immune repertoire, replacing the one that was causing disease.
Who Qualifies
Eligibility depends more on overall fitness than on a single number. Patients younger than 65 are typically considered good candidates, but between 65 and 70, the decision often comes down to organ function and general health rather than a strict age cutoff. Your heart, lungs, kidneys, and liver all need to be working well enough to tolerate high-dose chemotherapy. No randomized trial has compared transplant versus no transplant for patients over 65, so the conversation with your doctor is more individualized in that age range.
Step 1: Mobilization
Before stem cells can be collected, they need to be pushed out of your bone marrow and into your bloodstream, where they’re easier to harvest. This is called mobilization. You’ll receive injections of a growth factor, a hormone-like substance that stimulates your marrow to overproduce stem cells and release them into circulation. In some cases, a short round of chemotherapy is given first to jumpstart the process, followed by the growth factor.
For patients who don’t mobilize well on growth factor alone, a second medication can be added that blocks the signal stem cells use to anchor themselves in the marrow, effectively flushing more of them into the blood. Studies show that combining these two approaches allows nearly all myeloma patients (about 98%) to reach the minimum cell count needed for transplant, usually within a single collection session.
Step 2: Collection
Collection happens through a process called apheresis. Blood is drawn from one arm (or a central catheter), run through a machine that separates out the stem cells, and then returned to your body through another line. Each session takes roughly three to four hours. Most patients need only one session, though it can take up to four days depending on how well your cells mobilized. The collected stem cells are then frozen and stored until transplant day.
Step 3: Conditioning
This is the most physically demanding phase. You receive high-dose chemotherapy designed to destroy cancer cells throughout your body, including in the bone marrow. The doses are far higher than standard chemotherapy, which is precisely why you need the stem cell rescue afterward. For multiple myeloma, a single chemotherapy agent called melphalan is the most commonly used conditioning drug. Other cancers may require combination regimens. Some patients also receive radiation therapy during this phase.
Step 4: Infusion
The actual transplant is surprisingly anticlimactic. Your frozen stem cells are thawed and delivered through an IV catheter, much like a blood transfusion. The process itself takes a relatively short time and isn’t painful, though some patients notice a garlic-like taste or smell from the preservative used during freezing. From here, the cells do the work on their own, traveling through your bloodstream to your bone marrow.
Engraftment and Recovery
Engraftment is the point at which your transplanted stem cells begin producing new blood cells. For most patients, platelet counts recover in about 11 days, while white blood cell (neutrophil) recovery takes closer to 18 days. Until engraftment happens, you have virtually no immune system. This window is the highest-risk period for infection, and you’ll likely remain hospitalized or under close monitoring.
Bacterial infections are the most common complication in the early weeks, often linked to the combination of low white cell counts and mucositis, a painful inflammation of the mouth and digestive tract caused by the high-dose chemotherapy. After the first few months, viral infections become more of a concern than bacterial ones. Your immune system continues rebuilding for 3 to 12 months after transplant, and some patients take even longer to fully recover.
Risks and Complications
The conditioning chemotherapy hits fast-growing cells hard, and your gut lining is a major casualty. Mucositis can cause mouth sores, nausea, and difficulty eating. Gastrointestinal complications are among the most frequent early side effects, second only to bacterial infections.
More serious risks include organ damage from the chemotherapy and, over the long term, a small chance of developing a secondary cancer. In a large study of myeloma patients, secondary malignancies accounted for about 4% of deaths after transplant, while infection accounted for roughly 7%. The transplant procedure itself carries a low mortality risk, under 1% in the same study. The overwhelming majority of deaths in transplant patients (over 70%) are from the original disease eventually returning, not from the transplant itself.
Long-Term Outcomes
For multiple myeloma, outcomes vary widely. About 15% of patients in a large retrospective study achieved long-term remission of eight years or more after transplant, with a median progression-free survival exceeding 14 years in that group. A Mayo Clinic analysis found that roughly 9% of patients maintained remission for at least eight years without any maintenance therapy at all. These “exceptional responders” tend to have distinct disease characteristics identified at diagnosis.
Most patients, however, will eventually see their myeloma return. The transplant buys significant time, deepens the response to treatment, and for many people extends both survival and quality of life. Maintenance therapy after transplant, which involves taking lower-dose medication on an ongoing basis, has become standard practice to prolong remission further.
What Daily Life Looks Like Afterward
Recovery after discharge is measured in months, not weeks. The first three months are the most restrictive: you’ll need to avoid crowds, follow strict food safety rules, and watch carefully for signs of infection like fever. Most transplant centers recommend limiting contact with young children and avoiding anyone who’s sick during this period.
The full recovery window extends to about a year, sometimes longer. Energy levels gradually improve, but fatigue can linger for months. Most people return to work and normal activities somewhere in the three-to-six-month range, depending on their overall health and how their body responds. Your transplant team will monitor bloodwork regularly throughout this period to track how your immune system is rebuilding.